Literature DB >> 17448577

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Jens U Rüggeberg1, Michael S Gold, José-Maria Bayas, Michael D Blum, Jan Bonhoeffer, Sheila Friedlander, Glacus de Souza Brito, Ulrich Heininger, Babatunde Imoukhuede, Ali Khamesipour, Michel Erlewyn-Lajeunesse, Susana Martin, Mika Mäkelä, Patricia Nell, Vitali Pool, Nick Simpson.   

Abstract

Mesh：

Year:  2007        PMID： 17448577     DOI： 10.1016/j.vaccine.2007.02.064

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  101 in total

1.  Case discussion of an immediate serious reaction to hexavalent vaccine mistaken for anaphylaxis.

Authors:  Giovanna Zanoni; Leonardo Gottin; Attilio Boner; Giorgio Piacentini; Diego Peroni; Michael Gold
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 2.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.

Authors:  Tanya R Myers; Michael M McNeil; Carmen S Ng; Rongxia Li; Paige W Lewis; Maria V Cano
Journal:  Vaccine       Date:  2017-03-03       Impact factor: 3.641

4.  Anaphylaxis as an adverse event following immunisation.

Authors:  Michel Erlewyn-Lajeunesse; Jan Bonhoeffer; Jens U Ruggeberg; Paul T Heath
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

Review 5.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

6.  Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia.

Authors:  C-M Baxter; H J Clothier; K P Perrett
Journal:  Hum Vaccin Immunother       Date:  2018-05-10       Impact factor: 3.452

7.  Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK.

Authors:  Michel Erlewyn-Lajeunesse; Sandra Dymond; Ingrid Slade; Helen L Mansfield; Rosie Fish; Owen Jones; Jonathan R Benger
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

8.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

9.  Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.

Authors:  Ingrid B Rabe; Elaine R Miller; Marc Fischer; Susan L Hills
Journal:  Vaccine       Date:  2014-12-09       Impact factor: 3.641

10.  Template protocol for clinical trials investigating vaccines--focus on safety elements.

Authors:  Jan Bonhoeffer; Egeruan B Imoukhuede; Grace Aldrovandi; Novilia S Bachtiar; Eng-Soon Chan; Soju Chang; Robert T Chen; Rohini Fernandopulle; Karen L Goldenthal; James D Heffelfinger; Shah Hossain; Indira Jevaji; Ali Khamesipour; Sonali Kochhar; Mamodikoe Makhene; Elissa Malkin; David Nalin; Rebecca Prevots; Ranjan Ramasamy; Sarah Sellers; Johan Vekemans; Kenneth B Walker; Pam Wilson; Virginia Wong; Khalequz Zaman; Ulrich Heininger
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.